Methods Article for a Study Protocol: Study Design and Baseline Characteristics for Aldosterone Synthase Inhibition in Chronic Kidney Disease
American Journal of Nephrology · 2024
DOI: 10.1159/000534808 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift American Journal of Nephrology, 2024. Verfasst von Katherine R Tuttle und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, University of Washington, Spokane, Washington, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucosides, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 20-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Aldosterone synthase (AS) inhibition may overcome increased aldosterone production in response to renin-angiotensin system inhibition. BI 690517 is an AS inhibitor under investigation for chronic kidney disease (CKD).
Methods
This multinational, phase II, double-blind study (NCT05182840) investigated the efficacy and safety of daily oral BI 690517, with or without empagliflozin 10 mg, in participants with CKD. The primary endpoint was change from baseline in urine albumin:creatinine ratio (UACR) at week 14. Between February 18, 2022, and December 30, 2022, 714 adults already treated by angiotensin-converting enzyme inhibitor (30.5%) or angiotensin receptor blocker (69.8%) were randomized (1:1) to an 8-week run-in to assign background empagliflozin (n = 356) or placebo (n = 358). Participants in each group were then randomized (1:1:1:1) to a 14-week treatment period with BI 690517 (3 mg, 10 mg, or 20 mg) or placebo. Of the 714 participants who entered run-in, 586 were randomized to the treatment period. They were predominantly men (66.6%) of white race (58.4%) with a mean (standard deviation [SD]) age of 63.8 (11.3) years. Type 2 diabetes was present in 414 participants (70.6%). The baseline mean (SD) estimated glomerular filtration rate was 51.9 (17.7) mL/min/1.73 m2, and median (interquartile range) UACR was 426.3 mg/g (205.3–888.5).
Conclusion
This study will inform dose selection for further clinical development and determine whether BI 690517, with or without background empagliflozin, has a favorable safety profile and potential for additive kidney protection in participants with CKD already treated with a renin-angiotensin system inhibitor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Department of Medicine, University of Washington, Spokane, Washington, USA.
- Complications Research, Steno Diabetes Center Copenhagen, Herlev, Denmark.
- Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
- Vth Department of Medicine, University Medical Center Mannheim, Heidelberg University, Heidelberg, Germany.
- Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA.
- Boehringer Ingelheim Ltd, Bracknell, UK.
Zitieren
APA
Tuttle, K. R., Rossing, P., Hauske, S. J., Cronin, L., Hussain, J., de Zeeuw, D., & Heerspink, H. J. L. (2024). Methods Article for a Study Protocol: Study Design and Baseline Characteristics for Aldosterone Synthase Inhibition in Chronic Kidney Disease. American Journal of Nephrology. https://doi.org/10.1159/000534808
Vancouver
Tuttle KR, Rossing P, Hauske SJ, Cronin L, Hussain J, de Zeeuw D, et al. Methods Article for a Study Protocol: Study Design and Baseline Characteristics for Aldosterone Synthase Inhibition in Chronic Kidney Disease. American Journal of Nephrology. 2024. doi:10.1159/000534808
BibTeX
@article{Tuttle2024,
author = {Tuttle, Katherine R and Rossing, Peter and Hauske, Sibylle J and Cronin, Lisa and Hussain, Joanna and de Zeeuw, Dick and Heerspink, Hiddo J L},
title = {Methods Article for a Study Protocol: Study Design and Baseline Characteristics for Aldosterone Synthase Inhibition in Chronic Kidney Disease},
journal = {American Journal of Nephrology},
year = {2024},
doi = {10.1159/000534808}
}
EUVIMED